125031 May 2026

In the medical field, is the Biologics License Application (BLA) number assigned by the FDA to Neulasta (pegfilgrastim) .

The number also serves as a specific article identifier in high-level physics and engineering research: 125031

Neulasta is a leukocyte growth factor used to decrease the incidence of infection—manifested by febrile neutropenia—in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. In the medical field, is the Biologics License

Recent supplemental applications (e.g., BLA 125031/S-0202) have added critical safety information to the drug's labeling, including increased risks of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) when used alongside chemotherapy or radiation for breast and lung cancer. Scientific Literature Identifier In the medical field

In technical troubleshooting, it appears as a timestamp or unique ID in system logs for home automation platforms like Homey Pro , specifically within the Audit app used for debugging.

The number appears most prominently as a regulatory and scientific identifier, particularly within the medical and physical sciences. Pharmaceutical Identifier (BLA 125031)